Phibro Animal Health (PAHC)
(Delayed Data from NSDQ)
$22.01 USD
+1.12 (5.36%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $22.00 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$22.01 USD
+1.12 (5.36%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $22.00 -0.01 (-0.05%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Zacks News
Phibro Animal Health (PAHC) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of 20.59% and 4.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Phibro (PAHC) Stock Jumps 10.2%: Will It Continue to Soar?
by Zacks Equity Research
Phibro (PAHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Broad Portfolio to Aid Patterson Companies' (PDCO) Q1 Earnings
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal first-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments on the back of comprehensive product offerings.
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Countdown to Phibro (PAHC) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Phibro (PAHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
ICU Medical, Inc. (ICUI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
ICU Medical (ICUI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Phibro Animal Health (PAHC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Phibro (PAHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quipt Home Medical Corp. (QIPT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Quipt Home Medical (QIPT) delivered earnings and revenue surprises of -500% and 1.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) fourth-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
Warby Parker Inc. (WRBY) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Warby Parker (WRBY) delivered earnings and revenue surprises of 20% and 0.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zimmer Biomet (ZBH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 1.52% and 0.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Phibro (PAHC) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Phibro (PAHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Buy, Sell or Hold McKesson (MCK) Before Q1 Earnings?
by Zacks Equity Research
McKesson's (MCK) first-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Is Phibro (PAHC) Stock Worth Retaining in Your Portfolio Now?
by Zacks Equity Research
Phibro's (PAHC) Animal Health business, supported by the flourishing Vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.
Baxter (BAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to benefit from positive pricing impact and new product launches. However, supply-chain issues are likely to have raised expenses in the quarter.
Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Value Trader Highlights: Great Lakes Dredge & Dock, HanesBrands, Lands' End, Phibro Animal Health and Wolverine World Wide
by Zacks Equity Research
Great Lakes Dredge & Dock, HanesBrands, Lands' End, Phibro Animal Health and Wolverine World Wide are part of the Zacks Value Trader article.
How to Invest in Small Cap Value Stocks in 2024
by Tracey Ryniec
Historically, small cap value stocks have been among the best performers. Here's how to screen for them.
Are Investors Undervaluing National Vision (EYE) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Baxter International (BAX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Beat the Market Like Zacks: Freshpet, AudioEye, Walmart in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Phibro (PAHC) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Phibro (PAHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).